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A B S T R A C T
Purpose
In this large cohort of Hodgkin’s lymphoma survivors with long follow-up, we estimated the impact
of treatment regimens on premature ovarian failure (POF) occurrence and motherhood, including
safety of nonalkylating chemotherapy and dose-response relationships for alkylating chemother-
apy and age at treatment.
Patients and Methods
The Life Situation Questionnaire was sent to 1,700 women treated in European Organisation for
Research and Treatment of Cancer and Groupe d’E´tude des Lymphomes de l’Adulte trials
between 1964 and 2004. Women treated between ages 15 and 40 years and currently not using
hormonal contraceptives (n  460) were selected to assess occurrence of POF. Cumulative POF
risk was estimated using the life-table method. Predictive factors were assessed by Cox
regression analysis.
Results
Median follow-up was 16 years (range, 5 to 45 years). Cumulative risk of POF after alkylating
chemotherapy was 60% (95% CI, 41% to 79%) and only 3% (95% CI, 1% to 7%) after
nonalkylating chemotherapy (doxorubicin, bleomycin, vinblastine, and dacarbazine; epirubicin,
bleomycin, vinblastine, and prednisone). Dose relationship between alkylating chemotherapy and
POF occurrence was linear. POF risk increased by 23% per year of age at treatment. In women
treated without alkylating chemotherapy at age younger than 32 years and age 32 years or older,
cumulative POF risks were 3% (95% CI, 1% to 16%) and 9% (95% CI, 4% to 18%), respectively.
If menstruation returned after treatment, cumulative POF risk was independent of age at
treatment. Among women who ultimately developed POF, 22% had one or more children after
treatment, compared with 41% of women without POF.
Conclusion
Nonalkylating chemotherapy carries little to no excess risk of POF. Dose-response relationships
for alkylating chemotherapy and age at treatment are both linear. Timely family planning is
important for women at risk of POF.
J Clin Oncol 30:291-299. © 2011 by American Society of Clinical Oncology
INTRODUCTION
High cure rates (80% to 90%) of Hodgkin’s lym-
phoma (HL) and a predominant incidence in pa-
tients age 20 to 44 years have resulted in many
patients wishing to start or complete a family after
treatment.1-3 Since 1964, the European Organisa-
tion for Research and Treatment of Cancer
(EORTC) Lymphoma Group (in collaboration with
the Groupe d’Etude des Lymphomes de l’Adulte
[GELA] since 1993), has treated patients with HL
uniformly in clinical trials. From 1982 onward, the
aim of these trials has also focused on reduction of
treatment-related toxicity.
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Whereas in men fertility is relatively easily studied by analysis of
sperm counts and follicle stimulating hormone,4,5 hormone measure-
ments in women are influenced by menstrual cycle patterns and hor-
monal contraceptive use. Pregnancy outcomes and documentation of
(premature) cessation of menses offer reliable information. Prema-
ture ovarian failure (POF), defined as irreversible amenorrhea lasting
more than 12 months before the age of 40 years, can develop during
treatment or occur years later, reflecting early depletion of oocytes
caused by gonadotoxic treatment. Interaction between the gonado-
toxic drug and menstrual cycle in women can be complex as regards
time. Women may cease menstruating during therapy, recover there-
after, and become pregnant but still experience POF or early meno-
pause (between ages 40 and 44 years) later on.6
Few reports on ovarian failure and infertility after treatment for
HL have provided long-term follow-up.7,8 Most have involved low
patient numbers or women treated in childhood.8-10 Information on
both menstrual status and number of children is even rarer. In
addition, almost no data have been published on nonalkylating chem-
otherapy, which is presently considered first-choice therapy in early-
stage disease.9 In 2009, the Life Situation Questionnaire (LSQ) was
sent to HL survivors treated within EORTC-GELA trials. This ques-
tionnaire addressed in detail fertility and parenthood. It offered the
opportunity to study fertility outcome in a large cohort of long-term
survivors and compare the influence of various treatment regimens on
POF occurrence and age at menopause as well as on female fertility by
comparing chances of motherhood after HL.
PATIENTS AND METHODS
Women
Overall, 3,020 women were included in nine consecutive randomized
clinical trials conducted in 13 European countries between 1964 and 2004
(Table 1). Protocols of the H1 through H9 trials are detailed in published
reports.2,11-19 Patients presented with histologically proven, previously un-
treated HL. Exclusion criteria were concomitant or previous malignancies or
serious comorbidities. Treatment administered was recorded prospectively,
including chemotherapy type, number of cycles, radiotherapy field, and dose.
In 2008, after human investigations committee approval, current addresses
were tracked for all 2,712 women alive at last follow-up. For 1,700 women
from five countries and 114 hospitals, a recent address was obtained (Fig 1).
Questionnaire
The LSQ addresses issues not yet available in any validated questionnaire.
It contains the following items: parenthood after HL; education, work, and
insurance; health and social situation; and support received during treatment.
Occurrence of menopause was evaluated based on the following question: “At
this moment, do you have a menstrual cycle? If no, is this because of a)
menopause b) removal of uterus and/or ovaries c) pregnancy or breastfeeding
d) continuous contraceptive use or e) other, please specify.” Age at last men-
struation was also recorded, including whether this last menstruation was
more than 1 year ago. Occurrence of immediate menopause during treatment
was evaluated based on the following question: “During first treatment for
Hodgkin’s lymphoma, did you have a spontaneous menstrual cycle? If no, did
your menstrual cycle spontaneously return after treatment?” In the LSQ, data
on embryo, oocyte, and ovarian cryopreservation were collected. However,
none of these options had resulted in any live births among our patient group.
Of 1,700 women approached, 964 (57%) returned the questionnaire and
provided written informed consent. A nonresponder analysis performed to
compare those who did not reply with those who did indicated almost no
differences. Responders came more often from earlier trials and thus were
slightly less often treated with nonalkylating chemotherapy and radiotherapy
above the diaphragm. Disease stage distribution was similar in responders
and nonresponders.
Selection of Women
For the POF analysis, we included all women age 15 years or older at
treatment who had completed the questions on menstruation and menopause
(n  945). Women who were (post) menopausal before treatment were
excluded, as were those with unknown menstrual status because of current
contraceptive use. Women who had had sterilizing surgery (removal of uterus
and/or ovaries) at an unknown date and women with menopause resulting
from an unrelated medical event were also excluded.
Because only effects of primary treatment were considered, women with
nonresponse or progression during treatment were excluded; those who expe-
rienced a relapse were censored at time of relapse. Rates of progression or
relapse were low (82 of 964 patients; 8.5%). Women with a second malignancy
were censored at time of that diagnosis, as were those with surgical menopause
at time of surgery and those with continuous progestagen use at start of use, if
dates were provided. Analysis was performed on treatment actually received,
not on an intention-to-treat basis. Sixteen women received several chemother-
apy regimens (protocol violation) and were excluded from analysis. After
exclusions, 575 women were suitable for analysis; 460 were younger than 40
years of age at treatment for HL and therefore at risk for POF. They were
included in analyses with POF as the end point (Fig 1).
Definitions
POF was defined as menopause before age 40 years. Menopause was
defined as cessation of menstruation at least 1 year before the date of the survey
in the absence of pregnancy, breastfeeding, continuous use of progestagens or
other medication causing amenorrhea, or surgical removal of uterus and/
or ovaries.
Women administered chemotherapy were grouped into those treated
with regimens without alkylating agents (doxorubicin, bleomycin, vinblas-
tine, and dacarbazine [ABVD]20; epirubicin, bleomycin, vinblastine, and
prednisone [EBVP]21) and those treated with alkylating chemotherapy
(mechlorethamine, vincristine, procarbazine, and prednisone [MOPP]22;
MOPP/doxorubicin, bleomycin, and vinblastine [MOPP/ABV hybrid
[RSQB]23; cyclophosphamide, doxorubicin, vincristine, bleomycin, etopo-
side, procarbazine, and prednisone [standard BEACOPP]24). Of all women
included, 11% to 12% received ABVD, 18% to 19% received EBVP, 6%
received MOPP, 33% to 36% received MOPP/ABV, and 4% received standard
BEACOPP. None received dose-escalated BEACOPP (Appendix Table A1,
online only). Cycles administered at reduced doses were considered full cycles.
The number of cycles was used to estimate the amount of alkylating chemo-
therapy administered, counting one cycle of MOPP/ABV or BEACOPP as
equivalent to 0.5 MOPP cycle. In two trials, maintenance chemotherapy
for 2 years was administered: vinblastine 10 or 6 mg, or 6 mg weekly for 3
months alternating with procarbazine daily 150 mg for 3 weeks, with a gap
of at least 4 weeks in between.11,12 Because the cumulative procarbazine
dose in this regimen was 9 g/m2, approximately comparable to six MOPP
cycles, procarbazine-containing maintenance therapy was considered
equivalent to six cycles of MOPP.
Information on smoking, education level, and number of biologic and
adopted children was obtained from the LSQ questionnaire. Education level
was grouped into low, middle, and high: low comprised primary school and
the lower level of secondary school (corresponding to International Standard
Classification of Education [ISCED] levels25 0, 1, and 2); middle, the higher
levels of secondary school (ISCED levels 3 and 4); and high, higher education
and university (ISCED levels 5 and 6).
Statistical Analysis
The aim of this study was to estimate the impact of HL treatment
regimens on POF occurrence (primary end point), menopause, and mother-
hood. A cohort analysis was performed. Women were observed from start of
HL treatment until POF (n 77), age 40 years (n 202), relapse (n 39),
second malignancy (n  8), surgical menopause (n  4), first continuous
progestagen use (n 10), or date of LSQ completion if younger than 40 years
and still menstruating (n 120).
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Table 1. Patient Demographics and Clinical Characteristics
Characteristic
Replied to LSQ
All Women Included
in H1 to H9 TrialsIncluded in Analysis Excluded From Analysis
No. % No. % No. %
No. of women 575 19* 389 13* 3,020†
Country
France 204 35 192 49 1,409 47
the Netherlands 311 54 159 41 1,037 34
Belgium 46 8 28 7 315 10
Italy 14 2 9 2 102 3
Other 0 0 1  1 157 5
Age at treatment start, years
Median 30 27 29
Range 15-56 10-70 6-71
15-24 192 33 169 43 1,054 35
25-34 195 34 109 28 976 32
35-44 137 24 44 11 529 18
 45 51 9 67 17 461 15
Unknown 0 0 0 0 1  1
Age at LSQ reply, years
Median 49 40 NA
Range 25-76 24-84 NA
Follow-up duration, years
Median 15 12 NA
Range 5-45 5-45 NA
Period of treatment
1964-1976‡ 42 7 6 2 242 8
1977-1993§ 217 38 97 25 1,117 37
1994-2004 316 55 286 74 1,661 55
Disease stage
I, II 514 89 344 88 2,685 89
III, IV 61 11 45 12 335 11
B symptoms
Absent 405 70 277 71 2,084 69
Present 159 28 105 27 853 28
Unknown 11 2 7 2 83 3
Initial treatment
Chemotherapy 456 79 351 90 2,353 78
No alkylating agents 192 33 160 41 933 31
Alkylating agents 264 46 191 49 1,410 47
Unknown 0 0 2  1 10  1
Radiotherapy 541 94 349 90 2,738 91
Above diaphragm 405 70 286 74 1,963 65
Below diaphragm 136 24 63 16 772 26
Unknown 0 0 0 0 3  1
Staging laparotomy 40 7 4 1 230 8
Ovarian transposition 7 1 1  1 66 2
Second-line treatment 53¶ 9 29 7 507 17
Second malignancy 18 3 10 3 135 4
Smoking
Never 299 52 216 56 Not known
Ever 274 48 169 43
Unknown 2  1 4 1
Education level
Low 155 27 114 29 Not known
Middle 183 32 126 32
High 228 40 141 36
Unknown 9 2 8 2
NOTE. Because of rounding, percentages may exceed or fall short of 100%.
Abbreviations: LSQ, Life Situation Questionnaire; NA, not applicable.
Percent of all women eligible.
†All women who were deceased, did not respond, and were lost to follow-up included.
‡Comprises H1 (n  21) and H2 (n  21) trials.
§Comprises H5 (n  30), H3B4 (n  11), H6 (n  64), and H7 (n  81) trials; first part of H34 trial (n  24); and start of H8 trial (n  8).
Comprises second part of H34 trial (n  27) and H8 (n  133) and H9 (n  156) trials.
¶Observations censored at time of relapse or second malignancy, unless menopause occurred before relapse or second malignancy.
POF and Fertility After Hodgkin’s Lymphoma
www.jco.org © 2011 by American Society of Clinical Oncology 293
Downloaded from ascopubs.org by Radboud University Nijmegen on January 26, 2020 from 131.174.248.154
Copyright © 2020 American Society of Clinical Oncology. All rights reserved.
Time to POF was defined as time from start of treatment to POF
occurrence, to age 40 years, or to LSQ reply, whichever came first. Cumu-
lative risks of POF and exact binomial 95% CIs were estimated using the
life-table method.26 Univariable analysis of factors influencing POF occur-
rence and menopause age was performed using the Kaplan-Meier method
and log-rank test. A multivariable analysis of prognostic factors with
regard to POF occurrence was performed using Cox regression analysis.
Variables entered into the model were treatment age; chemotherapy (alky-
lating, nonalkylating) or cycles of alkylating chemotherapy in MOPP
equivalents (no alkylating chemotherapy, four cycles of MOPP equiva-
lent,  four cycles of MOPP equivalent); radiotherapy (above or below
diaphragm or on iliac region); second-line treatment (no, yes); treatment
period (1964 to 1976, 1977 to 1993, 1994 to 2004); clinical stage (I to II, III
to IV); presence of B symptoms (no, yes); smoking (never, ever); and
education level (low, middle, high). A stepwise selection procedure was
used. The likelihood ratio test was used to compare a model with age or
cycles of MOPP equivalent as continuous variables against models with age
or cycles of MOPP equivalent as dichotomous, categorical, logarithmic, or
continuous quadratic variables (results shown in part). By receiver oper-
ating characteristic analysis, the optimal cutoff for treatment age was
evaluated in predicting POF occurrence. Exact binomial 95% CIs for
sensitivity and specificity were calculated. All statistical tests were two
sided, and statistical significance was defined as a P value of less than .01 to
adjust for multiple comparisons.
RESULTS
Characteristics for all women included in the trials (N  3,020)
and those selected for analysis are listed in Table 1 (n 575) and
Table 2 (selection POF, n 460). Women selected were more often
treated 10 or more years ago, because the menstrual status of
women using hormonal contraceptives (on average younger)
could not be evaluated. Women selected for analysis of POF were
on average younger at treatment because those age 40 years or older
were no longer at risk for POF. Clinical stage distribution was
similar in the groups.
After median follow-up of 16 years (range, 5 to 45 years), 77 of
460 women developed POF. To avoid overestimation of POF inci-
dence compared with general population data, we hypothesized all
women excluded from analysis because of use of hormonal contracep-
tives still had a menstrual cycle. Being younger, these women were
more probably fertile than those who did not use hormonal contra-
ceptives. Under this most conservative approach possible, the cor-
rected incidence of POF in our cohort was 20.1% (95% CI, 15.9% to
24.8%) compared with 0.9% (95% CI, 0.3% to 1.5%) in the gen-
eral population.27
Twenty-three percent of women were treated with radiother-
apy alone (of whom one received iliac radiotherapy), 33% with
combined chemoradiotherapy without alkylating agents and 44%
with combined radiotherapy and alkylating agents. The distribu-
tion of treatment and other characteristics according to POF oc-
currence is shown in Table 2. Sixty-nine (34%) of 202 women
treated with alkylating chemotherapy developed POF, whereas
among women treated with nonalkylating chemotherapy, four
(3%) of 151 did. Among women treated with iliac-region radio-
therapy, 11 (41%) of 27 had POF, but all had also been treated with
alkylating chemotherapy.
Multivariable Analysis
Figures 2A to 2D illustrate treatment (alkylating chemother-
apy, yes or no) and treatment age influence on age of menopause.
Women treated with alkylating chemotherapy had an age-adjusted
hazard ratio (HR) of 12.31 (95% CI, 5.90 to 25.68; P  .001) for
POF occurrence compared with women not treated with alkylating
chemotherapy (Table 2). The cumulative risk of POF for treatment
with alkylating chemotherapy (n 202) was 60% (95% CI, 41% to
79%) and only 3% (95% CI, 1% to 7%) or 6% (95% CI, 2% to
20%) for treatment with nonalkylating chemotherapy (ABVD or
EBVP, n 151) or radiotherapy only (n 107), respectively. The
adjusted HRs were 9.84 (95% CI, 4.62 to 20.97; P  .001) for
women treated with fewer than four cycles of MOPP-equivalent
chemotherapy and 21.10 (95% CI, 9.49 to 46.93; P  .001) for
All female patients
(H1–H9)
(N = 3,020)
Questionnaires sent
(n = 1,700)
All responders
(n = 964)
With information on
menstrual cycle
and menopause
(n = 948)
Past puberty at start
of treatment
(n = 945)
To be assessed for
menopause after treatment
(n = 875)
To be assessed for
menopause after treatment
(n = 858)
To be assessed for
menopause after treatment
(n = 604)
Selection for analysis of
menopause at any age
(n = 575)
Selection for analysis of POF
(n = 460)
No questionnaire received
  Deceased (n = 15)
  Wrong address (n = 213)
  Refusal (n = 21)
  No reply (n = 487)
No questionnaire sent
  Deceased (n = 509)
  Lost to follow-up (n = 811)
Insufficient reply to
parenthood questions
(n = 16)
Treated before age 15
(n = 3)
Menopause before treatment
(n = 70)
Sterilizing surgery at 
  unknown date (n = 12)
Other medical causes of 
  menopause* (n = 5)
Current contraceptive use
(n = 254)
Progression or nonresponse
  to treatment (n = 13)
Received more than 1
  chemotherapy regimen (n = 16)
Age ≥ 40 at start of treatment
(n = 115)
Fig 1. CONSORT diagram; selection of women included in analysis. (*)
Menopause after thyroid problems, curettage (Asherman’s syndrome), syn-
drome of Mayer-Rokitansky-Ku¨ster, cerebrovascular accident, and endometriosis
(one patient case in each category).
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women treated with four or more cycles compared with those
treated without alkylating chemotherapy (Table 2). Number of
cycles of MOPP equivalent (categorical) was highly significant
(P  .001) when entered into the Cox regression model for POF
risk, which included only women treated with alkylating chemo-
therapy, indicating a significant dose-response relationship (Fig 3).
Comparing the model with cycles of MOPP equivalent as contin-
uous variable against the model with cycles of MOPP of equivalent
as quadratic or logarithmic variable showed no statistically signif-
icant difference (P  .92 and P  .30, respectively), indicating a
linear dose-response relationship. The HR per cycle of alkylating
chemotherapy was 1.50 (95% CI, 1.37 to 1.64; P .001).
There was a 23% increase in POF risk per year of age at treatment
(Table 2). Comparing the model with treatment age as continuous
variable against the model with treatment age as quadratic or logarith-
mic variable showed no statistically significant difference (P .16 and
P .19, respectively), indicating a linear relationship. However, when
actual calendar age attained at end of follow-up was used as a time
variable in survival analysis, the difference between age groups at
treatment was much smaller. The total cumulative risks of POF were
17% (95% CI, 9% to 30%) for those younger than age 25 years at
treatment and 32% (95% CI, 20% to 47%) for those 35 years of age or
older, respectively, but the difference was mostly the result of direct
menopause during treatment (n 94). If only women with recurring
menstruation after treatment were included, the cumulative risks of
POF were 17% (95% CI, 9% to 30%) and 16% (95% CI, 7% to 35%),
respectively. This illustrates that with long-term follow-up, women
without direct acute ovarian failure at time of treatment had a com-
parative cumulative risk of developing POF, regardless of treat-
ment age.
We further evaluated prognostic value of treatment age for POF
occurrence by calculating receiver operating characteristic curves for
Table 2. Patient Characteristics in Relation to Presence of POF
Characteristic
Total POF No POF
P 
Model With All Variables Final Model
No. % No. % No. % HR 95% CI P HR 95% CI P
No. of women 460 77 17† 383 83†
Age at start of treatment, years  .001 1.23‡ 1.16 to 1.30  .001 1.23‡ 1.16 to 1.30  .001
15-24 192 42 14 18 178 46
25-34 195 42 44 57 151 39
35-39 73 16 19 25 54 14
Treatment period .004
1964-1976 42 9 1 1 41 11 1.00 —
1977-1993 188 41 43 56 145 38 1.80 0.22 to 15.05 .59
1994-2004 230 50 33 43 197 51 1.52 0.18 to 13.02 .70
Disease stage  .001
I, II 409 89 54 70 355 93 1.00 —
III, IV 51 11 23 30 28 7 1.32 0.68 to 2.56 .41
B symptoms  .001
Absent 323 70 36 47 287 75 1.00 —
Present 130 28 40 52 90 24 1.32 0.80 to 2.17 .27
Unknown 7 1 1 1 6 2
Initial treatment
Chemotherapy 353 77 73 95 280 73  .001
No alkylating agents 151 33 4 5 147 38 1.00 1.00
Alkylating agents§ 202 44 69 90 133 35  .001 12.31 5.90 to 25.68  .001
1.5 to three cycles of MOPP
equivalent 155 34 44 57 111 29 8.49 3.75 to 19.23  .001 9.84 4.62 to 20.97  .001
 Four cycles of MOPP
equivalent 47 10 25 29 22 6 15.04 6.14 to 36.87  .001 21.10 9.49 to 46.93  .001
Radiotherapy 429 93 69 90 360 94  .001
Above diaphragm 319 69 53 69 266 69 1.00
Below diaphragm, not iliac region 83 18 5 6 78 20 0.83 0.32 to 2.16 .70
Iliac region 27 6 11 14 16 4  .001 0.76 0.35 to 1.66 .49
Smoking .186
Never 237 52 35 45 202 53 1.00 —
Ever 222 48 42 55 180 47 0.86 0.54 to 1.38 .54
Unknown 1  1 0 0 1  1
NOTE. Because of rounding, percentages may exceed or fall short of 100%.
Abbreviations: HR, hazard ratio; MOPP, mechlorethamine, vincristine, procarbazine, and prednisone; POF, premature ovarian failure.
Log-rank test.
†Percent of all women included.
‡Age analyzed as continuous variable.
§Either alkylating agents as dichotomous (yes or no) or categorical variable (no alkylating agents, 1.5 to three cycles of MOPP equivalent,  four cycles of MOPP
equivalent) were entered into multivariable model; difference between chemotherapy without alkylating agents and radiotherapy only was not statistically significant.
Radiotherapy on iliac region (no or yes) and combination variable of radiotherapy and alkylating chemotherapy (no alkylating chemotherapy and no radiotherapy
below diaphragm, radiotherapy below diaphragm but no alkylating chemotherapy, alkylating chemotherapy but no radiotherapy below diaphragm, or both) were not
statistically significant.
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several cutoff values. The effect of age on POF occurrence was smaller
in women treated with alkylating chemotherapy (area under the
curve, 0.75; 95% CI, 0.54 to 0.96) compared with women treated
without alkylating chemotherapy (area under the curve, 0.68; 95% CI,
0.61 to 0.76; Figs 4A, 4B). In the latter, the best cutoff value was
treatment before age 32 years versus treatment at a later age. Sensitivity
was 88% (95% CI, 83% to 91%) and specificity was 71% (95% CI,
65% to 77%). For a cutoff at age 30 years (cutoff usually selected in
literature), specificity was 63% (95% CI, 57% to 69%). We found no
statistically significant interaction between treatment age as continu-
ous (P  .18) or categorical variable (P  .61) and the number of
cycles of MOPP equivalent as categorical variable. The cumulative
risks for POF in women treated at age younger than 32 years and age 32
years or older without alkylating chemotherapy were 3% (95% CI, 1%
to 16%) and 9% (95% CI, 4% to 18%), respectively. The HR for POF
associated with age 32 years or older at treatment was 15.65 (95% CI,
1.88 to 130; P  .01) compared with age younger than 32 years in
women treated without alkylating chemotherapy. Other possible risk
factors for POF were also assessed. Smoking, B symptoms, clinical
stage, and period of treatment had no significant influence on POF
occurrence (Table 2).
Overall, 94 women developed acute menopause during first-line
treatment: none, 14 (15%), 41 (44%), and 39 (41%) when ages 15 to
24, 25 to 34, 35 to 44, and 45 years or older, respectively. Sixty-four
women (68%) were treated with alkylating chemotherapy. Of 77
women who developed POF, 17 (22%) had at least one biologic child
after treatment; nine were treated before age 25 years, and eight were
from 25 to 32 years of age. This must be compared with 124 (41%) of
300 of women without POF who had at least one biologic child
after treatment.
DISCUSSION
To our knowledge, this is the first large study to evaluate POF occur-
rence based on data provided by women themselves, with treatment
administered in prospective clinical trials and without masking
through contraceptive use. The results highlight several major facts.
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Fig 2. Time to menopause after treatment for Hodgkin’s lymphoma by age at start of treatment: (A) 15 to 24, (B) 25 to 34, (C) 35 to 44, and (D) 45 years or older.
Alk, chemotherapy containing alkylating agents with or without radiotherapy (n  264); Alk, chemotherapy not containing alkylating agents with or without
radiotherapy or radiotherapy alone (n  311).
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First, we showed nonalkylating chemotherapy carries little excess risk
of POF. However, even in this treatment group, chemotherapy ad-
ministered in women age 32 years or older resulted in an elevated risk
of POF development (9% v0.9% in general population). Second, POF
occurrence is mainly influenced by alkylating chemotherapy use; the
dose relationship between alkylating chemotherapy and POF occur-
rence is linear. Finally, we can offer insight into the influence of
treatment-related POF on motherhood.
The emerging use of (dose-escalated) BEACOPP seems to repre-
sent a step backward compared with ABVD from the fertility view-
point. Behringer et al28 found levels of acute menopause during
treatment of 32% after BEACOPP baseline, 55% after COPP/ABVD,
and even 67% after escalated BEACOPP. Escalated BEACOPP con-
tains almost double the cyclophosphamide dose and the same procar-
bazine dose as BEACOPP, so two cycles of escalated BEACOPP can be
roughly equated to 1.5 cycles of MOPP, resulting in an HR for POF
of 9.84.
We confirmed the dose-response relationship for procarbazine
found by De Bruin et al7 in a study based on medical records not
excluding oral contraceptive use. They found an HR of 12.3 for POF
after chemotherapy (any type), whereas no significant effect was ob-
served for nonalkylating chemotherapy, used in 50 of 331 women
only. The rare reports documenting the effect of nonalkylating chem-
otherapy on fertility concern limited numbers (24 to 70 women) and
sparse data.9,29-31
Our data show an increase in risk of POF of 23% per year of age at
treatment (HR, 1.23), corrected for dose of alkylating chemotherapy
administered. The prognostic value of treatment age for POF occur-
rence is most pronounced in women receiving nonalkylating chemo-
therapy. The cutoff age found (32 years) is close to that generally used
(30 years).
A disadvantage, but simultaneously a strength, of our analysis
concerns the information on women currently using hormonal con-
traception, who had to be excluded because ongoing menstruation
could mask menopause. A consequence of excluding these on average
younger and probably more fertile women is that POF incidences
might be inflated. In the comparison with POF incidence in the gen-
eral population, this has been corrected by using the most conservative
estimate possible, assuming that all hormonal contraception users are
still menstruating.
Our results are based on a questionnaire filled in by women
treated under clinical trial conditions. Correct and current informa-
tion on menstrual status is best obtained from women themselves, not
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Fig 3. Cox regression estimation of probability of patients free of premature
ovarian failure (POF) by time interval since chemotherapy (censored at age 40
years) in 460 women treated for Hodgkin’s lymphoma by dose of alkylating
chemotherapy, adjusted for age at treatment. MOPP, mechlorethamine, vincris-
tine, procarbazine, and prednisone.
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occurrence by treatment age for women treated (A) without and (B) with
alkylating chemotherapy.
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from medical records. However, every questionnaire-based study suf-
fers from response bias. In our study, responders differed slightly from
nonresponders in the treatment received but not in treatment age or
disease stage. No information on education level was available
for nonresponders.
In any survival analysis, the question of censoring is important. In
our study, limited numbers were censored because of relapse, second
malignancy, or other reasons, so censoring probably did not influence
the study results.
Our report is among the few to offer information on the impact
of POF on motherhood. Despite treatment toxicity experienced, for-
tunately, one fourth of women delivered one or more children before
POF occurrence. Conversely, our report also indicates that women
with proven fertility after treatment can still be confronted with infer-
tility problems at a later stage.
In summary, women treated with nonalkylating chemotherapy
younger than 32 years of age have little to no excess POF risk. Alkylat-
ing chemotherapy carries a serious POF risk, with HRs of 10 to 21,
depending on dose administered. Women with recurring menstrua-
tion after treatment should be informed about their potentially short-
ened fertility lifespan.
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